|
|
重症肺炎药物治疗的研究进展
|
Abstract:
重症肺炎是一种呼吸系统急危重疾病，发展迅速、病情凶险，可导致严重的并发症。在其发病初期，正确使用药物，能够及时挽救患者生命。关于重症肺炎研究是广泛的，在宿主免疫反应、疾病严重程度的评估、微生物原因、多药耐药病原体的危险因素、诊断测试和治疗选择方面吸引了不同的观点。本文就重症肺炎的药物治疗研究进展综述如下。
Severe pneumonia is an acute and critical disease of the respiratory system, which develops rapidly and is dangerous, and can lead to serious complications. In the early stage of its onset, the correct use of drugs can save the patient’s life in time. Research on severe pneumonia is extensive, attract-ing diverse perspectives on host immune responses, assessment of disease severity, microbial causes, risk factors for multidrug-resistant pathogens, diagnostic tests, and treatment options. In this article, the research progress of drug therapy for severe pneumonia is summarized as follows.
| [1] | Wheeler, A.P. and Bernard, G.R. (2007) Acute Lung Injury and the Acute Respiratory Distress Syndrome: A Clinical Review. The Lancet, 369, 1553-1564. https://doi.org/10.1016/S0140-6736(07)60604-7 |
| [2] | Jain, S., Self, W.H., Wunderink, R.G., Fakhran, S., Balk, R., Bramley, A.M., et al. (2015) Community-Acquired Pneumonia Requiring Hos-pitalization among U.S. Adults. The New England Journal of Medicine, 373, 415-427.
https://doi.org/10.1056/NEJMoa1500245 |
| [3] | Jackson, C.D., Burroughs-Ray, D.C. and Summers, N.A. (2020) Clinical Guideline Highlights for the Hospitalist: 2019 American Thoracic Society/Infectious Diseases Society of Ameri-ca Update on Community-Acquired Pneumonia. Journal of Hospital Medicine, 15, 743-745. https://doi.org/10.12788/jhm.3444 |
| [4] | Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. (2011) Guidelines for the Management of Adult Lower Respiratory Tract Infections. Clinical Microbiology and Infection, 17, E1-E59.
https://doi.org/10.1111/j.1469-0691.2011.03672.x |
| [5] | Mufson, M.A. and Stanek, R.J. (1999) Bacteremic Pneu-mococcal Pneumonia in One American City: A 20-Year Longitudinal Study, 1978-1997. The American Journal of Medi-cine, 107, 34S-43S.
https://doi.org/10.1016/S0002-9343(99)00098-4 |
| [6] | Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., et al. (2004) Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia. American Journal of Respiratory and Critical Care Medicine, 170, 440-444. https://doi.org/10.1164/rccm.200311-1578OC |
| [7] | Martínez, J.A., Horcajada, J.P., Almela, M., et al. (2003) Addi-tion of a Macrolide to a Beta-Lactam-Based Empirical Antibiotic Regimen Is Associated with Lower In-Hospital Mortal-ity for Patients with Bacteremic Pneumococcal Pneumonia. Clinical Infectious Diseases, 36, 389-395. https://doi.org/10.1086/367541 |
| [8] | Weiss, K., Low, D.E., Cortes, L., et al. (2004) Clinical Characteristics at Initial Presentation and Impact of Dual Therapy on the Outcome of Bacteremic Streptococcus pneumoniae Pneumonia in Adults. Canadian Respiratory Journal, 11, 589-593. https://doi.org/10.1155/2004/461392 |
| [9] | Torres, A., Rank, D., Melnick, D., et al. (2019) Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospi-tal-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points. Open Forum Infectious Diseases, 6, ofz149. https://doi.org/10.1093/ofid/ofz149 |
| [10] | Martin-Loeches, I., Lisboa, T., Rodriguez, A., et al. (2010) Combination Antibiotic Therapy with Macrolides Improves Survival in Intubated Patients with Community Acquired Pneumonia. Intensive Care Medicine, 36, 612-620.
https://doi.org/10.1007/s00134-009-1730-y |
| [11] | Sligl, W.I., Asadi, L., Eurich, D.T., Tjosvold, L., Marrie, T.J. and Majumdar, S.R. (2014) Macrolides and Mortality in Critically Ill Patients with Community-Acquired Pneumonia: A Sys-tematic Review and Meta-Analysis. Critical Care Medicine, 42, 420-432. https://doi.org/10.1097/CCM.0b013e3182a66b9b |
| [12] | Rodriguez, A., Mendia, A., Sirvent, J.M., et al. (2007) Combination Antibiotic Therapy Improves Survival in Patients with Community-Acquired Pneumonia and Shock. Criti-cal Care Medicine, 35, 1493-1498.
https://doi.org/10.1097/01.CCM.0000266755.75844.05 |
| [13] | Siddiqui, A.H. and Koirala, J. (2021) Methicillin Re-sistant Staphylococcus aureus. StatPearls Publishing, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK482221 |
| [14] | Puren, A.J., Feldman, C., Savage, N., et al. (1995) Pat-terns of Cytokine Expression in Community Acquired Pneumonia. Chest, 107, 1342-1349. https://doi.org/10.1378/chest.107.5.1342 |
| [15] | Ferna？ndez-Serrano, S., Dorca, J., Coromines, M., et al. (2003) Mo-lecular Inflammatory Responses Measured in Blood of Patients with Severe Community-Acquired Pneumonia. Clinical and Vaccine Immunology, 10, 813-820.
https://doi.org/10.1128/CDLI.10.5.813-820.2003 |
| [16] | De Pascale, G., Bello, G. and Antonelli, M. (2011) Steroids in Severe Pneumonia: A Literature Review. Minerva Anestesiologica, 77, 902-910. |
| [17] | Venkatesh, B., Finfer, S., Co-hen, J. and Myburgh, J. (2018) Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. The New England Journal of Medicine, 378, 797-808. https://doi.org/10.1056/NEJMoa1705835 |
| [18] | Briel, M., Spoorenberg, S.M.C., Snijders, D., et al. (2018) Corticosteroids in Patients Hospitalized with Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Meta-Analysis. Clinical Infectious Diseases, 66, 346-354. https://doi.org/10.1093/cid/cix801 |
| [19] | Annane, D., Renault, A., Brun-Buisson, C., et al. (2018) Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. The New England Journal of Medicine, 378, 809-818. https://doi.org/10.1056/NEJMoa1705716 |
| [20] | Esperatti, M., Ferrer, M., Giunta, V., et al. (2013) Validation of Predictors of Adverse Outcomes in Hospital-Acquired Pneumonia in the ICU. Critical Care Medicine, 41, 2151-2161. https://doi.org/10.1097/CCM.0b013e31828a674a |
| [21] | Vincent, J.-L., Sakr, Y., Singer, M., et al. (2020) Prevalence and Outcomes of Infection among Patients in Intensive Care Units in 2017. JAMA, 323, 1478-1487. https://doi.org/10.1001/jama.2020.2717 |
| [22] | Metlay, J.P., Waterer, G.W., Long, A.C., et al. (2019) Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medi-cine, 200, e45-e67.
https://doi.org/10.1164/rccm.201908-1581ST |
| [23] | Han, J., Gatheral, T. and Williams, C. (2020) Procalcitonin for Patient Stratification and Identification of Bacterial Co-Infection in COVID-19. Clinical Medicine (London), 20, e47. https://doi.org/10.7861/clinmed.Let.20.3.3 |
| [24] | National Institutes of Health (2023) Information on Covid-19 Treatment, Prevention and Research. Covid-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ |
| [25] | Beigel, J.H., Tomashek, K.M., Dodd, L.E., et al. (2020) Remdesivir for the Treatment of Covid-19—Final Report. The New England Journal of Medicine, 383, 1813-1826. https://doi.org/10.1056/NEJMoa2007764 |
| [26] | Muthuri, S.G., Venkatesan, S., Myles, P.R., et al. (2014) Effective-ness of Neuraminidase Inhibitors in Reducing Mortality in Patients Admitted to Hospital with Influenza A H1N1pdm09 Virus Infection: A Meta-Analysis of Individual Participant Data. The Lancet Respiratory Medicine, 2, 395-404. https://doi.org/10.1016/S2213-2600(14)70041-4 |
| [27] | Dutkowski, R. (2010) Oseltamivir in Seasonal Influenza: Cumulative Experience in Low- and High-Risk Patients. Journal of Antimicrobial Chemotherapy, 65, ii11-ii24. https://doi.org/10.1093/jac/dkq012 |
| [28] | Tchesnokov, E.P., Feng, J.Y., Porter, D.P., et al. (2019) Mechanism of In-hibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 11, 326. https://doi.org/10.3390/v11040326 |
| [29] | Sheahan, T.P., Sims, A.C., Graham, R.L., et al. (2017) Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses. Science Translational Medicine, 9, eaal3653. https://doi.org/10.1126/scitranslmed.aal3653 |
| [30] | Agostini, M.L. andres, E.L., Sims, A.C., et al. (2018) Corona-virus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio, 9, e00221-18.
https://doi.org/10.1128/mBio.00221-18 |
| [31] | de la Torre, M.C., Torán, P., Serra-Prat, M., et al. (2016) Serum Lev-els of Immunoglobulins and Severity of Community-Acquired Pneumonia. BMJ Open Respiratory Research, 3, e000152.
https://doi.org/10.1136/bmjresp-2016-000152 |
| [32] | de la Torre, M.C., Palomera, E., Serra-Prat, M., et al. (2016) IgG2 as an Independent Risk Factor for Mortality in Patients with Community-Acquired Pneumonia. Journal of Critical Care, 35, 115-119.
https://doi.org/10.1016/j.jcrc.2016.05.005 |
| [33] | Justel, M., Socias, L., Almansa, R., et al. (2013) IgM Levels in Plasma Predict Outcome in Severe Pandemic Influenza. Journal of Clinical Virology, 58, 564-567. https://doi.org/10.1016/j.jcv.2013.09.006 |
| [34] | Shao, Z., Feng, Y., Zhong, L., et al. (2020) Clinical Efficacy of In-travenous Immunoglobulin Therapy in Critical Ill Patients with COVID-19: A Multicentre Retrospective Cohort Study. Clinical & Translational Immunology, 9, e1192.
https://doi.org/10.1002/cti2.1192 |
| [35] | Lanza, M., Polistina, G.E., Imitazione, P., Annunziata, A., Di Spirito, V., Novella, C., et al. (2020) Successful Intravenous Immunoglobulin Treatment in Severe COVID-19 Pneumonia. IDCases, 21, e00794.
https://doi.org/10.1016/j.idcr.2020.e00794 |
| [36] | Xie, Y., Cao, S., Li, Q., Chen, E., Dong, H., Zhang, W., et al. (2020) Effect of Regular Intravenous Immunoglobulin Therapy on Prognosis of Severe Pneumonia in Patients with COVID-19. Journal of Infection, 81, 318-356.
https://doi.org/10.1016/j.jinf.2020.03.044 |
| [37] | Tagami, T., Matsui, H., Fushimi, K. and Yasunaga, H. (2015) In-travenous Immunoglobulin and Mortality in Pneumonia Patients with Septic Shock: An Observational Nationwide Study. Clinical Infectious Diseases, 61, 385-392.
https://doi.org/10.1093/cid/civ307 |
| [38] | Zhou, Z., Xie, S., Zhang, J., et al. (2020) Short-Term Moderate-Dose Cor-ticosteroid Plus Immunoglobulin Effectively Reverses COVID-19 Patients Who Have Failed Low-Dose Therapy. https://doi.org/10.21203/rs.3.rs-34078/v1 |
